Adial Pharmaceuticals Inc. (NASDAQ: ADIL) Jumps 21% Following Grant of Patent Notice For Genetic Diagnostic Panel

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) jumped 21.19%  after the company announced plans to foray into the genetic testing market following the grant of a Notice of Allowance from the US patent and Trademark Office (USPTO). 

Adial receives a patent related to AD04

The patent notice is related to using the genetic diagnostic panel in combination with Adial’s flagship product, AD04, in treating Alcohol Use Disorder. Equally, the Notice of Allowance covers the patent related to using the combination of the generic diagnostic panel and AD04 in Opioids Use Disorder (OUD) treatment. 

Adial CEO William Stilley said that the new patent relating to using the genetic diagnostic panel combined with AD04 for AUD and OUD treatment is a significant milestone. He said that they believe that patient genetic testing can be utilized to identify AD04 beneficiaries. Stilley said they have been using the genetic panel covered by the patent in the present ONWARDTM third phase study. With the patent granted, Adial expects genetic diagnostics to be a big part of the company’s commercial strategy in the future.

ONWARD Phase 3 underway in Europe 

The Phase 2B AD04 study concept undertaken at the University of Virginia, and the ONWARD third phase AD04 study presently underway in Europe, show that AUD has a substantial genetic nexus. This is consistent with Adial’s hypothesis regarding specific genotypes with a significant impact on whether a person suffering from AUD or OUD will likely react to therapy with AD04.

Once issued, the recently granted patent will give market exclusivity for the AD04 genetic diagnostic test, potentially generating significant profit for the company. Adial has been granted a patent for its AD04 genetic diagnostic test. The company intends to enter the genetic testing market as a stand-alone commercial business line. If AD04 receives OUD approval, the company anticipates a possibility to commercialize a companion diagnostic test for OUD.

Leave a Comment

Your email address will not be published.